Mauro Schechter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8312294/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Is France Once Again Looking for a Scapegoat?. Pathogens and Immunity, 2021, 6, 149-152.	3.1	1
2	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. PLoS ONE, 2019, 14, e0222183.	2.5	1
3	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Research and Human Retroviruses, 2019, 35, 788-793.	1.1	8
4	Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials. Journal of the International AIDS Society, 2018, 21, e25077.	3.0	5
5	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV,the, 2018, 5, e172-e180.	4.7	28
6	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clinical Infectious Diseases, 2018, 67, 411-419.	5.8	50
7	Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. Clinical Infectious Diseases, 2018, 66, 1487-1491.	5.8	41
8	Reply to Kojima and Klausner. Clinical Infectious Diseases, 2018, 67, 1469-1470.	5.8	1
9	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission. Lancet, The, 2018, 392, 312-358.	13.7	230
10	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. Sexually Transmitted Diseases, 2017, 44, 306-309.	1.7	0
11	Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. Journal of Bone and Mineral Research, 2017, 32, 1945-1955.	2.8	38
12	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infectious Diseases, 2017, 4, ofx262.	0.9	65
13	The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. AIDS and Behavior, 2016, 20, 1527-1534.	2.7	41
14	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV,the, 2016, 3, e521-e528.	4.7	66
15	Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. Current HIV/AIDS Reports, 2016, 13, 241-255.	3.1	94
16	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clinical Infectious Diseases, 2016, 62, 1172-1177.	5.8	40
17	The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels. Aids, 2015, 29, 1355-1361.	2.2	16
18	Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals. PLoS Computational Biology, 2015, 11, e1004665.	3.2	46

#	Article	IF	CITATIONS
19	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 572-580.	5.8	132
20	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807.	27.0	2,232
21	Streamlining HIV Testing for HIV Preexposure Prophylaxis. Journal of Clinical Microbiology, 2015, 53, 179-183.	3.9	10
22	Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data. PLoS ONE, 2014, 9, e94636.	2.5	35
23	Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. Journal of the International AIDS Society, 2014, 17, 19480.	3.0	37
24	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infectious Diseases, The, 2014, 14, 820-829.	9.1	1,039
25	Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. Aids, 2014, 28, 869-874.	2.2	30
26	HIV-1 DNA predicts disease progression and post-treatment virological control. ELife, 2014, 3, e03821.	6.0	270
27	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infectious Diseases, The, 2013, 13, 587-596.	9.1	119
28	Short-Course Antiretroviral Therapy in Primary HIV Infection. New England Journal of Medicine, 2013, 368, 207-217.	27.0	194
29	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. Aids, 2013, 27, 973-979.	2.2	315
30	Rating evidence in treatment guidelines. Aids, 2013, 27, 1839-1846.	2.2	38
31	Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis. PLoS ONE, 2013, 8, e74057.	2.5	5
32	Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy. PLoS ONE, 2013, 8, e78287.	2.5	74
33	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Science Translational Medicine, 2012, 4, 151ra125.	12.4	807
34	Late Diagnosis of HIV Infection in Brazil Despite over 15 Years of Free and Universal Access to Treatment. AIDS Research and Human Retroviruses, 2012, 28, 1541-1542.	1.1	4
35	Prevalence and risk factors associated with syphilis in a cohort of HIV positive individuals in Brazil. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 252-258.	1.2	25
36	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	2.5	131

#	Article	IF	CITATIONS
37	Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis. PLoS ONE, 2011, 6, e22003.	2.5	93
38	The DART Trial: 'The Doctor's Dilemma' revisited. Journal of Antimicrobial Chemotherapy, 2011, 66, 964-967.	3.0	3
39	Estimating the Extent of Underreporting of Mortality Among HIV-Infected Individuals in Rio de Janeiro, Brazil. AIDS Research and Human Retroviruses, 2011, 27, 25-28.	1.1	16
40	Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Current Opinion in HIV and AIDS, 2010, 5, 70-77.	3.8	104
41	Monitoring Antiretroviral Therapy in Resource-Limited Settings: Balancing Clinical Care, Technology, and Human Resources. Current HIV/AIDS Reports, 2010, 7, 168-174.	3.1	15
42	Mortality after failure of antiretroviral therapy in sub‣aharan Africa. Tropical Medicine and International Health, 2010, 15, 251-258.	2.3	71
43	Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America. PLoS ONE, 2010, 5, e10490.	2.5	47
44	Longâ€Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatmentâ€Experienced Patients with Drugâ€Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. Clinical Infectious Diseases, 2010, 50, 605-612.	5.8	196
45	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 2010, 363, 2587-2599.	27.0	4,268
46	Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet, The, 2010, 376, 367-387.	13.7	431
47	Evaluation of Three Sampling Methods to Monitor Outcomes of Antiretroviral Treatment Programmes in Low- and Middle-Income Countries. PLoS ONE, 2010, 5, e13899.	2.5	13
48	Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil. Brazilian Journal of Infectious Diseases, 2009, 13, 272-5.	0.6	7
49	Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study). HIV Clinical Trials, 2009, 10, 368-374.	2.0	50
50	Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Tropical Medicine and International Health, 2009, 14, 1220-1225.	2.3	78
51	Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. Aids, 2009, 23, 2289-2300.	2.2	164
52	Overcoming resistance to existing therapies in HIVâ€infected patients: The role of new antiretroviral drugs. Journal of Medical Virology, 2008, 80, 565-576.	5.0	56
53	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 339-354.	27.0	699
54	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 355-365.	27.0	498

#	Article	IF	CITATIONS
55	The Use of Supplementary Techniques to Increase Recall of Sex Partners in a Network-Based Research Study in Rio de Janeiro, Brazil. Sexually Transmitted Diseases, 2008, 35, 674-678.	1.7	6
56	Validation of a Hierarchical Deterministic Record-Linkage Algorithm Using Data From 2 Different Cohorts of Human Immunodeficiency Virus-Infected Persons and Mortality Databases in Brazil. American Journal of Epidemiology, 2008, 168, 1326-1332.	3.4	65
57	Eearly loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 559-567.	3.3	275
58	Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil. PLoS ONE, 2008, 3, e1531.	2.5	51
59	Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. International Journal of Epidemiology, 2007, 36, 969-976.	1.9	120
60	Monotherapy with lopinavir/ritonavir. Expert Opinion on Investigational Drugs, 2007, 16, 735-741.	4.1	6
61	Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet, The, 2006, 367, 817-824.	13.7	1,030
62	Mortality of HIV-infected patients in low-income countries – Authors' response. Lancet, The, 2006, 368, 2207-2208.	13.7	2
63	Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil. Therapeutic Drug Monitoring, 2006, 28, 175-179.	2.0	16
64	Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. Journal of Infection, 2006, 52, 290-293.	3.3	20
65	Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 922-926.	5.6	128
66	Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. International Journal of STD and AIDS, 2006, 17, 473-478.	1.1	36
67	Treatment for Adult HIV Infection. JAMA - Journal of the American Medical Association, 2006, 296, 827.	7.4	755
68	Discordant immunological and virological responses to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2006, 58, 506-510.	3.0	40
69	Antiretroviral therapy in resource-poor settings: scaling up inequalities?. International Journal of Epidemiology, 2005, 34, 509-512.	1.9	27
70	Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology, 2005, 34, 979-986.	1.9	72
71	Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. PLoS Medicine, 2004, 1, e19.	8.4	220
72	Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naà ve adults: results of a 48-week open-label, equivalence trial (CNA3014). Current Medical Research and Opinion, 2004, 20, 1103-1114.	1.9	40

#	Article	IF	CITATIONS
73	Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Current Medical Research and Opinion, 2004, 20, 1115-1123.	1.9	21
74	Treatment for Adult HIV Infection. JAMA - Journal of the American Medical Association, 2004, 292, 251.	7.4	482
75	Antiretroviral Treatment for Adult HIV Infection in 2002. JAMA - Journal of the American Medical Association, 2002, 288, 222.	7.4	632
76	Reduced Risk of Tuberculosis among Brazilian Patients with Advanced Human Immunodeficiency Virus Infection Treated with Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2002, 34, 543-546.	5.8	161
77	Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. Aids, 2001, 15, 2129-2135.	2.2	43
78	Antiretroviral Therapy in Adults. JAMA - Journal of the American Medical Association, 2000, 283, 381.	7.4	951
79	HIV Disease Progression and V3 Serotypes in Brazil: Is B Different from B-Br?. AIDS Research and Human Retroviruses, 2000, 16, 953-958.	1.1	38
80	Dual and Recombinant Infections: An Integral Part of the HIV-1 Epidemic in Brazil. Emerging Infectious Diseases, 1999, 5, 65-74.	4.3	90
81	Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better?. Aids, 1999, 13, 97-102.	2.2	11
82	Genetic Variation and Susceptibilities to Protease Inhibitors among Subtype B and F Isolates in Brazil. Antimicrobial Agents and Chemotherapy, 1999, 43, 253-258.	3.2	35
83	Horizontal and Vertical Transmission of Human Immunodeficiency Virus Type 1 Dual Infections Caused by Viruses of Subtypes B and C. Journal of Infectious Diseases, 1998, 177, 227-231.	4.0	48
84	A Brazilian perspective. Lancet, The, 1997, 349, S29-S30.	13.7	3
85	Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes, 1996, 13, 69-81.	1.6	89
86	V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro. Memorias Do Instituto Oswaldo Cruz, 1995, 90, 683-685.	1.6	3
87	Sequence and Phylogenetic Analysis of Glycoprotein 120 of an HIV Type 1 Variant (GWGR) Prevalent in Brazil. AIDS Research and Human Retroviruses, 1995, 11, 1143-1145.	1.1	17
88	p24 antigenaemia in HIV-1 infected Brazilians correlates with other markers of disease progression. Journal of Infection, 1994, 29, 129-131.	3.3	4
89	Reactivity to Purified Protein Derivative and the Risk of Tuberculosis in HIV-infected Brazilian Patients. Chest, 1993, 104, 646.	0.8	3
90	Pulmonary Tuberculosis in Sputum-Negative Brazilian AIDS Patients. Chest, 1992, 101, 1184.	0.8	0